WAYNE, PA — Teleflex Incorporated (NYSE: TFX) announced that 400,000 patients have now been treated with the UroLift® System,1 a safe, effective and minimally invasive treatment option for benign prostatic hyperplasia (BPH), or enlarged prostate.2 The UroLift® System is the number one minimally invasive BPH procedure chosen by urologists and their patients in the U.S.3 The 5-year L.I.F.T. study results demonstrate UroLift® System durability with a surgical retreatment rate of about 2-3% per year and 13.6% total over 5 years.2
BPH is a non-cancerous enlargement of the prostate, occurring naturally as men age, which can cause urinary problems, decrease quality of life, and interrupt sleep.4 More than 14 million men in the U.S. seek treatment for the condition every year.3
“The UroLift® System is a proven treatment method in my practice for patients seeking relief from an enlarged prostate,” said Steven Gange, M.D., F.A.C.S., of Summit Urology Group and Associate Medical Director of the Teleflex Interventional Urology Business Unit. “For men with BPH who are looking to get off medications, the UroLift® System can be an excellent minimally invasive option that provides rapid relief and low risk of permanent side effects.”
Teleflex recently conducted a survey of 1,000 U.S. men aged 45+ who are experiencing BPH symptoms to better understand the treatment journey and patient behavior surrounding BPH.5
Key findings include:
- 70% of men surveyed, who were as young as 45, indicated medications were recommended as at least one option for treating BPH.6
- Nearly half of the respondents on medication (44%) are interested in alternative treatment options.7
“Urologists can change appropriate BPH patients’ journeys for the better, with confidence, by offering them the UroLift® System,” said Kevin Hardage, President and General Manager of Teleflex Interventional Urology. “At Teleflex, we are honored to play an important role in enhancing the quality of life of hundreds of thousands of men with BPH.”
*No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study.
- Management estimate based on product sales as of December 2022. Data on file Teleflex Interventional Urology.
- Roehrborn, Can J Urol 2017.
- U.S. 2022 estimates based on US Market Model 2022-24 (5-17-22 FINAL), which is in part based on Symphony Health PatientSource® 2018-21, as is and with no representations/warranties, including accuracy or completeness.
- Speakman, BJUI 2014.
- Survey of US men aged 45+ who have experienced symptoms commonly associated with BPH (enlarged prostate), conducted by Teleflex in 2022. Data on file, n=1000.
- Survey of US men aged 45+, who have been diagnosed with BPH (enlarged prostate), are suffering from at least one urinary symptom, and who spoke to their doctor about their BPH treatment, conducted by Teleflex in 2022. Data on file, n=1,001
- Survey of US men aged 45+, who have been diagnosed with BPH (enlarged prostate), are suffering from at least one urinary symptom, who did not get a treatment recommendation from their doctor about their BPH treatment, or did get a recommendation from their doctor about their BPH treatment and chose medications, conducted by Teleflex in 2022. Data on file, n=714
- Rukstalis, Prostate Cancer and Prostatic Dis 2018.
- AUA BPH Guidelines 2003, 2021.
- McVary, J Sex Med 2016.
- Roehrborn, J Urology 2013.
Thanks for visiting! Looking for some Chester County pride? We got you covered! Shop our MyChesCo store and show your love for Chester County, Pennsylvania. We got shirts, hats, and more – all with a unique ChesCo flair. Plus, proceeds from each purchase helps support our mission of bringing reliable information and resources to the people of Chester County.